Cellmed launches four new products targeting year-end digestive concerns

Biotech company Cellmed said Wednesday it will launch four new products targeting the year-end season, reflecting changes in eating habits driven by an increase in gatherings and dining out.

Among the new offerings is Glutase Forte, a nutraceutical fermented enzyme product designed to support the breakdown of a range of dietary components — from carbohydrates and protein to gluten. The product incorporates CMD, a gluten-degrading enzyme developed using Cellmed's proprietary technology, and achieved a gluten breakdown rate of up to 99 percent under the company's own testing conditions. Each single-serving packet (2 grams) contains 1,000 milligrams of CMD, 1,000,000 units of amylase and 8,000 units of protease.

In addition to amylase and protease, each packet combines a gluten-degrading enzyme and a casein-degrading enzyme. The formula also includes papaya extract powder alongside plant-based synergistic ingredients — chicory dietary fiber and pea protein powder.

"Eating patterns tend to become irregular at year-end due to various gatherings and dining out," said Cellmed CEO Jang Bong-geun. "The new products reflect the concerns that shift with the season and living environment, incorporating specialized ingredients and technology tailored to each product."